Navigation Links
Differences Over Pathways Developed by Oncologists and MCOs May Create Conflict Over Prescribing Decisions in Early-Line Treatment

BURLINGTON, Mass., Aug. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that clinical pathways developed by physician groups are not preventing oncologists from prescribing their preferred therapies for advanced non-small-cell lung cancer (NSCLC), but that pathways developed by managed care organizations (MCOs) are more restrictive. Seventy-two percent of surveyed oncologists currently participating in a clinical pathways program for stage IV nonsquamous (NSQ) NSCLC indicated that both Roche/Genentech/Chugai's Avastin and Roche's Tarceva were permitted in the first line while 66 percent reported that Pfizer's Xalkori was permitted in this line. In general, these responses did not differ materially from the percentage of oncologists that would prefer to prescribe these drugs in these lines in the absence of clinical pathways. In contrast, less than a third of surveyed MCO pharmacy directors/medical directors whose plans are involved in pathways indicated these drugs were permitted in this line of therapy.                                                                                        

The U.S. Physician and Payer Forum report entitled Impact of Payer-Imposed Strategies on Market Access in NSCLC and Prostate Cancer: Clinical Pathways, Bundled Payments, and Accountable Care Organization Contracting finds that clinical pathways developed by oncologists tend to focus on the more advanced stages of cancer, such as stage IV NSQ and squamous NSCLC. MCOs, however, are focusing their efforts on less advanced NSCLC and prostate cancer. MCOs that do have pathways in place for more advanced cancer tend to present narrower lists of permitted therapies, which could create conflict among oncologists who wish to prescribe off pathway. In fact, this concern over their prescribing was listed among the key challenges for oncologists currently taking part in pathways.

The report also finds that bundled payments and accountable care organizations (ACOs) appear to be growing in prominence as MCOs seek to control costs. Often tied to chemotherapy and other therapies, bundled payments also commonly cover physician visits, hospitalizations and radiology. Surveyed payers believe that bundled payments can achieve reduced drug spending of 16 percent and medical spending of 17 percent, likely stemming from a focus on more cost-effective treatment.

"Payers want to control their costs in NSCLC and prostate cancer and these strategies will likely affect prescribing decisions. Across clinical pathways, bundled payments and ACOs, we see that payers see substantial potential to reduce costs without hurting outcomes," said Decision Resources Senior Director Roy Moore. "To achieve these goals, oncologists will likely be urged to change their prescribing decisions, particularly around the use of branded therapies and generics. Marketers of branded therapies must therefore cater their marketing strategies to these themes or risk reduced prescribing from oncologists."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. B12 Shots vs Sublingual B12 - US Vitamin Injections Discusses the Differences
2. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
3. A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
4. Breakthrough Method for Lipid Analysis in Fecal Material Developed; New Understanding of Diseases/Disorders Related to Gut Function Possible
5. ASCO Impact Report From Encuity Research Indicates Oncologists Are Likely to Shift Patient Treatment Plans
6. Oncologists restrict pharmaceutical sales rep access at accelerating rates
7. Cardinal Health Specialty Solutions, Health Alliance Plan Work With Michigan Oncologists to Improve Quality, Curb Costs of Cancer Care
8. Survey of Oncologists Reveals 98.9% of Physicians Experienced Cancer Drug Shortages in Last 12 Months
9. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
10. According to Surveyed Oncologists in the EU5, Zytiga Has Heavily Penetrated Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) and is Displacing Jevtana to Later-Line mCRPC
11. Despite the Recent Availability of Xtandi, Zytiga Continues to Dominate the Second-Line Metastatic Castrate-Resistant Prostate Cancer Setting, According to Surveyed U.S. Oncologists and Urologists
Post Your Comments:
(Date:11/30/2015)... iCAD, Inc. (Nasdaq: ICAD ) ... solutions for advanced image analysis and workflow tools ... Radiological Society of North American (RSNA) 2015 Annual ... November 29 to December 4, 2015. The company ... automated breast density assessment solution, PowerLook® Advanced Mammography ...
(Date:11/30/2015)... SALT LAKE CITY , Nov. 30, 2015 ... Systems (NYSE: VAR ) will exhibit a broader array ... meeting of the Radiological Society of North America ... The Varian exhibit at the meeting will feature X-ray components ... Cardinal CT tube, a line of products from Varian,s Claymount ...
(Date:11/30/2015)... Nov. 30, 2015  Novartis will demonstrate the strength ... th American Society of Hematology (ASH) Annual Meeting. ... as well as supportive care, including key findings in ... cell therapies. The ASH Annual Meeting will be held ... Novartis Oncology . "We will be presenting ...
Breaking Medicine Technology:
(Date:11/30/2015)... (PRWEB) , ... November 30, ... ... (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: Three ... learned from three innovative value-based care arrangements: Essentia Health and UCare, MissionPoint ...
(Date:11/30/2015)... ... November 30, 2015 , ... Vasont Systems, a top component ... (VUI) extension unites with Syncro Soft’s latest software update, oXygen XML editor Version ... with the latest release of oXygen® XML editor and the Vasont® CCMS. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Scott Newman MD, FACS ... select few plastic surgeons in the New York City area to utilize the ... world’s first heat-induced laser treatment for fat loss in the abdomen, flanks, and ...
(Date:11/30/2015)... ... November 30, 2015 , ... TransPack Volume 6 features 30 customizable ... from scrolling web-styled transitions to wipes with blur & drop shadow options. Utilize ... Seamlessly transition from one clip to the next with TransPack's easily customizable styles. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... strategic partnership at the Radiological Society of North America (RSNA) 2015 conference. ... providers of cutting-edge dictation and speech-enabled documentation software, announced their partnership today ...
Breaking Medicine News(10 mins):